Literature DB >> 2949923

Glucose intolerance and hypertension in north London: the Islington Diabetes Survey.

R D Forrest, C A Jackson, J S Yudkin.   

Abstract

In a general practice-based screening survey, 1040 (63.3%) of a randomly selected sample of 1644 people over the age of 40 years were examined for diabetes mellitus (DM) and hypertension (HT). Glucose intolerance was assessed by a single 2 h post-load blood glucose estimation and HT (diastolic blood pressure greater than or equal to 95mmHg by a single blood pressure reading) or being on anti-hypertensive treatment. The sample included 41 patients (2.1%) with known DM and 135 (12.5%) with known HT. Screening identified 27 (2.6%) new diabetics (16 women) and 43 subjects (4.1%) with impaired glucose tolerance (30 women). A further 30 known diabetics over the age of 40 and 12 diabetics under 40 were registered at the practice. The estimated prevalence of diabetes in the over 40s was 4.6% and in all ages was 1.6%. DM appeared to affect Afro-Caribbeans more commonly than Caucasians among those examined (5.9% versus 2.6%) though this difference did not reach statistical significance (z = 1.1106, p = 0.134). A total of 190 subjects (17.5%) were found to have HT, of whom 55 (5.1%) were newly diagnosed; 10.2% of the sample were on anti-hypertensive treatment, and in 79.3% of these the blood pressure was well controlled (diastolic less than 100 mmHg). HT was more common among known diabetics with a prevalence of 35.4%, of whom one-third were previously undiagnosed. HT affected Afro-Caribbeans significantly more commonly than Caucasians (z = 4.206, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 2949923     DOI: 10.1111/j.1464-5491.1986.tb00776.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

Review 1.  Rule of halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care.

Authors:  J T Hart
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

Review 2.  Impaired glucose tolerance.

Authors:  J S Yudkin; K G Alberti; D G McLarty; A B Swai
Journal:  BMJ       Date:  1990-09-01

3.  Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: comparison of record linkage with capture-recapture analysis.

Authors:  J N Harvey; L Craney; D Kelly
Journal:  J Epidemiol Community Health       Date:  2002-01       Impact factor: 3.710

4.  Prevalence of diabetes in a predominantly Asian community.

Authors:  J Yudkin; C A Jackson; R D Forrest
Journal:  BMJ       Date:  1989-03-25

5.  Diabetes and the general practitioner.

Authors:  J Nabarro
Journal:  J R Coll Gen Pract       Date:  1987-09

6.  Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London.

Authors:  F P Cappuccio; D G Cook; R W Atkinson; P Strazzullo
Journal:  Heart       Date:  1997-12       Impact factor: 5.994

7.  Evaluating screening policies for the early detection of retinopathy in patients with non-insulin dependent diabetes.

Authors:  S C Brailsford; R Davies; C Canning; P J Roderick
Journal:  Health Care Manag Sci       Date:  1998-10

8.  Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects.

Authors:  E Casiglia; G Zanette; A Mazza; V Donadon; C Donada; A Pizziol; V Tikhonoff; P Palatini; A C Pessina
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

9.  Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia.

Authors:  J S Yudkin; R D Forrest; C A Jackson; A J Ryle; S Davie; B J Gould
Journal:  Diabetologia       Date:  1990-04       Impact factor: 10.122

10.  The epidemiology of the haemoglobin level--a study of 1057 subjects in general practice.

Authors:  R D Forrest; C A Jackson; J S Yudkin
Journal:  Postgrad Med J       Date:  1987-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.